

# Long-Term Side Effects of Tyrosine Kinase Inhibitors in

Current Hematologic Malignancy Reports

11, 71-79

DOI: [10.1007/s11899-016-0309-2](https://doi.org/10.1007/s11899-016-0309-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Management of Polypharmacy in People with Cancer and Chronic Conditions. , 2016, , 261-286.		0
2	Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. <i>International Journal of Hematology</i> , 2017, 106, 398-410.	0.7	6
3	Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 547-559.	1.0	12
4	CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. <i>Blood Cancer Journal</i> , 2017, 7, e601-e601.	2.8	10
5	Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity. <i>Respiratory Medicine Case Reports</i> , 2017, 21, 154-157.	0.2	10
6	Using zebrafish models of leukemia to streamline drug screening and discovery. <i>Experimental Hematology</i> , 2017, 45, 1-9.	0.2	28
7	Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. <i>Frontiers in Pharmacology</i> , 2017, 8, 367.	1.6	78
8	Blockage of endoplasmic reticulum stress attenuates nilotinib-induced cardiotoxicity by inhibition of the Akt-GSK3 $\beta$ -Nox4 signaling. <i>European Journal of Pharmacology</i> , 2018, 822, 85-94.	1.7	10
11	Tratamiento de la enfermedad de injerto contra hu $\acute{e}$ sped cr $\acute{o}$ nica esclerodermiforme con imatinib: una perspectiva dermatol $\acute{o}$ gica. <i>Actas Dermo-sifiliogr<math>\acute{a}</math>ficas</i> , 2018, 109, 241-247.	0.2	4
12	Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective. <i>Actas Dermo-sifiliogr<math>\acute{a}</math>ficas</i> , 2018, 109, 241-247.	0.2	1
13	BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. <i>Haematologica</i> , 2018, 103, e10-e12.	1.7	26
15	Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 125.	1.1	24
16	Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. <i>Haematologica</i> , 2018, 103, 1825-1834.	1.7	55
17	Cotylenin A and tyrosine kinase inhibitors synergistically inhibit the growth of chronic myeloid leukemia cells. <i>International Journal of Oncology</i> , 2018, 52, 2061-2068.	1.4	2
18	Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 710-723.	0.2	23
19	Impact of Pharmaceutical Product Quality on Clinical Efficacy. , 2018, , 731-771.		0
20	Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 62.	3.5	19
21	siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 130, 66-70.	2.0	21

#	ARTICLE	IF	CITATIONS
22	Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. <i>Blood Reviews</i> , 2019, 33, 63-73.	2.8	38
23	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. <i>Cancer</i> , 2019, 125, 4033-4042.	2.0	3
24	Molecular Approaches to Treating Pediatric Leukemias. <i>Frontiers in Pediatrics</i> , 2019, 7, 368.	0.9	29
25	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27827.	0.8	50
26	Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 718-733.	1.2	9
27	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2019, , 1-23.		0
28	Reducing Wound Hemorrhage. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2019, 7, e2532.	0.3	0
29	Cardiac Interventional Procedures in Cardio-Oncology Patients. <i>Cardiology Clinics</i> , 2019, 37, 469-486.	0.9	5
30	Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5616.	1.8	20
31	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019, 381, 2315-2326.	13.9	257
32	Ichthyosiform Reaction Related to Ponatinib Therapy. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 873-875.	0.2	0
33	Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 162-166.	0.2	13
34	Targeting dementias through cancer kinases inhibition. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12044.	1.8	15
35	Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option. <i>Frontiers in Oncology</i> , 2020, 10, 1160.	1.3	3
36	Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 1106.	1.6	32
37	Reproducible and Characterized Method for Ponatinib Encapsulation into Biomimetic Lipid Nanoparticles as a Platform for Multi-Tyrosine Kinase-Targeted Therapy. <i>ACS Applied Bio Materials</i> , 2020, 3, 6737-6745.	2.3	21
38	Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia. <i>Cells</i> , 2020, 9, 1921.	1.8	11
39	Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors – A Single-Centre Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3269.	1.0	3

#	ARTICLE	IF	CITATIONS
40	State-of-the-art Review: Interventional Onco-Cardiology. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	3
41	Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway. Journal of Clinical Medicine, 2020, 9, 820.	1.0	16
42	Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib. Cardiovascular Toxicology, 2020, 20, 380-389.	1.1	7
43	Dasatinib as a Probable Cause of Bilateral Chylothorax in a Patient with Chronic Myeloid Leukemia: Case Report. SN Comprehensive Clinical Medicine, 2020, 2, 817-821.	0.3	1
44	Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica, 2021, 106, 1876-1882.	1.7	10
45	Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML. Cancer Research, 2020, 80, 2394-2406.	0.4	30
46	Follow-up issues in survivors of hematologic malignancies – Current stance and future perspectives. Blood Reviews, 2020, 44, 100674.	2.8	6
47	Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides. Cancer Letters, 2020, 482, 44-55.	3.2	6
48	Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers, 2020, 12, 826.	1.7	75
49	Dasatinib Induced Pleural Effusion and Pulmonary Hypertension. Clinical Cases in Cardiology, 2021, , 3-9.	0.0	0
50	Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System. International Journal of Nanomedicine, 2021, Volume 16, 1-14.	3.3	4
51	Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds. PLoS Neglected Tropical Diseases, 2021, 15, e0008425.	1.3	10
52	Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2021, 11, 632231.	1.3	8
53	System Genetics Including Causal Inference Identify Immune Targets for Coronary Artery Disease and the Lifespan. Circulation Genomic and Precision Medicine, 2021, 14, e003196.	1.6	7
54	Ponatinib-Associated Cardiac Tamponade. American Journal of Therapeutics, 2021, Publish Ahead of Print, .	0.5	1
55	Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. International Journal of Hematology, 2021, 114, 199-204.	0.7	5
56	Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib. Molecules, 2021, 26, 3300.	1.7	4
57	Sphingosine kinases are involved in the regulation of all-trans retinoic acid sensitivity of K562 chronic myeloid leukemia cells. Oncology Letters, 2021, 22, 581.	0.8	6

#	ARTICLE	IF	CITATIONS
58	Progressive Cellular Senescence Mediates Renal Dysfunction in Ischemic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1987-2004.	3.0	42
59	Potential Repositioning of Anti-cancer EGFR Inhibitors in Alzheimer's Disease: Current Perspectives and Challenging Prospects. <i>Neuroscience</i> , 2021, 469, 191-196.	1.1	33
60	A Case of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia That Was Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation. <i>Case Reports in Oncology</i> , 2021, 14, 1139-1143.	0.3	2
61	Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src. <i>Phytomedicine</i> , 2022, 95, 153705.	2.3	5
62	Pulmonary hypertension in patients with chronic myeloid leukemia. <i>Medicine (United States)</i> , 2021, 100, e26975.	0.4	3
63	Interventional Strategies in Cancer-induced Cardiovascular Disease. <i>Current Oncology Reports</i> , 2021, 23, 133.	1.8	2
64	Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study. <i>Leukemia and Lymphoma</i> , 2022, 63, 179-188.	0.6	0
65	Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance. <i>Cancers</i> , 2021, 13, 4820.	1.7	65
66	Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019. <i>JCO Global Oncology</i> , 2021, 7, 1429-1441.	0.8	13
67	Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2020, 147, 3160-3167.	2.3	34
68	Pushing the Envelope: Advancement of ADCs Outside of Oncology. <i>Methods in Molecular Biology</i> , 2020, 2078, 23-36.	0.4	22
69	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2020, , 711-732.		3
70	Cardiotoxicity of Novel Targeted Chemotherapeutic Agents. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 53.	0.4	17
71	Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature. <i>American Journal of Case Reports</i> , 2017, 18, 794-798.	0.3	4
72	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	0.8	26
73	Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway. <i>Oncotarget</i> , 2018, 9, 31958-31970.	0.8	29
74	Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib. <i>Internal Medicine</i> , 2020, 59, 2297-2300.	0.3	2
75	Quercetin Promotes Cell Cycle Arrest and Apoptosis and Attenuates the Proliferation of Human Chronic Myeloid Leukemia Cell Line-K562 Through Interaction with HSPs (70 and 90), MAT2A and FOXM1. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1523-1534.	0.9	15

#	ARTICLE	IF	CITATIONS
76	Examining the Early Period Effect of Nilotinib on Hearing: An Experimental Study. <i>Journal of International Advanced Otolaryngology</i> , 2020, 16, 77-86.	1.0	1
77	Thromboembolism in TKI therapy. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2018, 29, 473-486.	0.1	0
78	Large Vessel Vasculitis as a Possible Mechanism of Vascular Side Effects of Ponatinib: A Case Report. <i>Journal of Hematology (Brossard, Quebec)</i> , 2019, 8, 83-85.	0.4	0
80	Reacción ictiosiforme en relación con ponatinib. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 873-875.	0.2	0
83	STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 186-199.	2.0	1
84	A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. <i>Blood Research</i> , 2021, 56, 229-242.	0.5	19
85	Delivery strategies in treatments of leukemia. <i>Chemical Society Reviews</i> , 2022, 51, 2121-2144.	18.7	17
86	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. <i>Cancers</i> , 2022, 14, 983.	1.7	0
87	Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020). <i>Frontiers in Oncology</i> , 2022, 12, 826703.	1.3	6
88	Wavelength Independent Photo-Chemo Tri-Modal Combinatorial Renal Cell Carcinoma Therapy with Biocompatible Gold-Titanium Nanostars. <i>Advanced Therapeutics</i> , 2022, 5, 2100204.	1.6	0
89	Multi-Target Drugs for Blood Cancer in the Elderly: Implications of Damage and Repair in the Cardiovascular Toxicity. <i>Frontiers in Physiology</i> , 2021, 12, 792751.	1.3	1
95	Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, , .	0.1	0
96	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. <i>Blood Reviews</i> , 2022, 56, 100968.	2.8	16
97	Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29786.	0.8	2
98	Knowledge and awareness of leukaemia and its risks among the population of Saudi Arabia. <i>Informatics in Medicine Unlocked</i> , 2022, 31, 100971.	1.9	1
99	Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia. <i>Neoplasia</i> , 2022, 32, 100817.	2.3	5
100	Looking into the toxicity potential and clinical benefits of tyrosine kinase inhibitors (TKIs). , 2024, , 915-946.		0
101	CARDIOVASCULAR EFFECTS OF CHEMIO- AND RADIATION THERAPY IN CANCER PATIENTS: WHAT A CARDIO-ONCOLOGIST SHOULD KNOW (PART I). , 2022, 19, 169-176.		1

#	ARTICLE	IF	CITATIONS
102	Immunostimulation with chemotherapy of a ruthenium-arene complex via blockading CD47 signal in chronic myelogenous leukemia cells. <i>Journal of Inorganic Biochemistry</i> , 2023, 243, 112195.	1.5	2
103	Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
104	Dasatinib-Associated Spontaneous Gluteal Hematoma and Hemorrhagic Shock. <i>American Journal of Therapeutics</i> , 2023, 30, 153-155.	0.5	1
105	Endocrine-related adverse conditions induced by tyrosine kinase inhibitors. <i>Annales D'Endocrinologie</i> , 2023, 84, 374-381.	0.6	8
106	Inclusion body myositis triggered with long-term imatinib use. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311685.	0.5	0
107	Coronary Revascularization in Patients With Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2023, 25, 143-158.	0.4	1
112	Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	24